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Background: Stroke patients with development of delirium have unfavorable outcomes,
higher mortality, longer hospitalizations, and a greater degree of dependence after dis-
charge. Studies suggest that delirium is associated with abnormal immunological responses
and a resultant increase in inﬂammatory markers.
Objective: Our aim was to determine whether there is an entity relationship between
delirium, inﬂammation and acute ischemic stroke (AIS).
Methods: Sixty AIS patients admitted to the hospital were consecutively recruited. Delirium
was diagnosed with the clinical assessment according to the Statistical Manual of Mental
Disorders, Fifth Edition (DSM-V) criteria. Enzyme-linked immunosorbent assay (ELISA) was
used to measure serum levels of Interleukin-1 beta (IL-1 beta), Interleukin 18 (IL-18), Tumor
Necrosis Factor-alpha (TNF-alpha), Brain-Derived Neurotrophic Factor (BDNF), and Neuron
Speciﬁc Enolase (NSE) at admission.
Results: Eleven (18.3%) of 60 patients were diagnosed with delirium, and the majority (n = 8,
72.7%) was the hypoactive type. Delirious and non-delirious patients had similar demo-
graphic and clinical features. Delirious patients had signiﬁcantly higher lengths of hospital
stay, National Institutes of Health Stroke Scale (NIHSS) at admission and discharge com-
pared to non-delirious patients. In addition, there was no signiﬁcant statistical difference
between delirious and non-delirious patients with AIS in respect of levels of TNF-alpha, IL-1
beta, IL-18, BDNF and NSE. This study suggests that delirium is not scarce in patients with
AIS admitted to the non-intensive stroke unit, and that delirium developing after AIS seems
not to be associated with serum TNF-alpha, IL-1 beta, IL-18, BDNF and NSE but is associated
with length of hospital stay and stroke severity.
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Delirium is a common neuropsychiatric clinical syndrome
characterized primarily by a disturbance of awareness,
attention and additional cognitive functions such as memory,
language and perception, and which can also affect sleep,
psychomotor activity and emotions. Other main features of
delirium are the development of disturbances usually lasting
hours to days and a tendency to a ﬂuctuation in the level of
consciousness during the course of the day [1,2]. It may occur
due to general medical conditions and their treatment,
substance use or withdrawal, multiple etiologies or an
unknown etiology [1,3]. Delirium is not only a manifestation
of clinical syndromes but is also related to increased mortality
[4], longer stays in hospital and poorer physical and social
functioning in patients [5,6]. Therefore, delirium is an
important clinical problem in hospitalized patients.
Its prevalence has been reported to be from 14% to 87% in
critically ill patients [7]. Stroke is one of the recognized
predisposing factors for delirium [8]. Although delirium affects
10–48% of patients with acute stroke [9], a meta-analysis
indicated that, pre-stroke poor vision, impaired vision, pre-
stroke dementia, metabolic disorders, Glasgow Coma Scale
score less than 15 on admission, and inability to lift both arms
on admission have been reported to be independent factors
associated with delirium following stroke [8,10,11]. Similar to
other general medical conditions, stroke patients with deliri-
um have higher mortality, stay longer in hospital, and have
high risk of institutionalization [11,12].
Pathophysiology of delirium remains unclear and poorly
understood [13]. Because of the complex causation of delirium,
a single cause or mechanism for this clinical condition will
probably not be discovered [14]. It is possible to conclude that
in most cases of delirium there is interaction of multiple
biological precipitating and predisposing factors resulting in
disruption of neuronal networks in the brain, associated with
cognitive functions [13,14].
Many potential pathophysiological contributors to delirium
have been studied. These studies include pro-inﬂammatory
markers in addition to neurotransmitters, electrolytes, meta-
bolic disturbances, and genetic factors [14]. Capri et al.
reported that high levels of preoperative Interleukin 6 (IL-6)
levels, Interleukin 8 (IL-8) and Interleukin 10 (IL-10) were
independently associated with post-operative delirium [15].
Kazmierski et al. reported that patients with raised concen-
trations of Interleukin 2 (IL-2) and Tumor Necrosis Factor-
alpha (TNF-a) measured the day after coronary-artery bypass
graft surgery were more likely to develop delirium [16].
Moreover, some authors found signiﬁcantly more IL-6 and
IL-8 levels above the detection limit in patients with delirium
who were acutely admitted to hospital compared to patients
who did not have delirium [17]. In addition, it has been
reported that at admission to an intensive care unit, Brain-
Derived Neurotrophic Factor (BDNF) and Neuron Speciﬁc
Enolase (NSE) levels were signiﬁcantly higher in delirious
patients than in nondelirious patients [18]. However, the role
of proinﬂammatory cytokines, BDNF and NSE in delirium
following acute stroke is unknown. Previous studies on this
topic have been conducted in patients with other medicalconditions. In this study, we aimed to investigate whether the
occurrence of delirium in patients with acute ischemic stroke
(AIS) is associated with serum TNF-alpha, Interleukin 1beta
(IL-1 beta), Interleukin 18 (IL-18), BDNF and NSE on admission.
2. Methods
2.1. Study population
Sixty patients with acute ischemic stroke admitted to our
hospital within the ﬁrst 24 h of stroke onset were prospectively
included in the study. These patients were followed up in the
non-intensive stroke unit. The inclusion criteria were clinical
presentation of acute ischemic stroke, age 18 years or older. The
study exclusion criteria included: (1) An admission to hospital
after the ﬁrst 24 h, (2) a diagnosis of transient ischemic attack
(TIA), intracerebral hemorrhage (ICH) or subarachnoid hemor-
rhage (SAH), (3) the existence of impaired consciousness, severe
aphasia or dysphasia, (4) a history of brain tumor with or
without systemic malignancy, (5) a history of acute myocardial
infarction, (6) the existence of renal dysfunction and symptom-
atic peripheral arterial disease, (7) a history of infection in the
last three months, acquired infections after the application,
autoimmune and immunosuppressive diseases or using immu-
nosuppressive drugs, (8) a history of trauma or surgical history
within one month, (9) the existence of acute/chronic inﬂamma-
tory disease of the gastrointestinal tract, rheumatic disease, (10)
a diagnosis of metabolic syndrome and (11) use of antidepres-
sant or other psychotropic medication in the last month.
Informed consent was obtained after providing verbal and
written information to participants or nearest relatives when
relevant. The study was performed in accordance with the
Helsinki declaration and approved by the local ethics committee
of the Necmettin Erbakan University, Meram Medical Faculty.
2.2. Stroke case ascertainment
Stroke was deﬁned as the presence of rapidly developing focal
neurological signs or symptoms of vascular origin that
persisted for more than 24 h. All events were adjudicated by
a panel of at least two neurologists. A general medical history
was collected and physical and neurological examinations,
standard laboratory tests, and 12-lead electrocardiogram were
performed on all patients upon admission. The ischemic
lesion and affected brain region were assessed and conﬁrmed
both by clinical examination and computed tomography (CT)
and/or brain magnetic resonance imaging (MRI) during
hospitalization for acute stroke. Stroke subtype was classiﬁed
according to Trial of ORG 10172 in Acute Stroke Treatment
(TOAST) criteria [19]. Location of the infarct lesion was
determined by radiological ﬁndings and the Oxfordshire
classiﬁcation criteria were used [20]. Stroke severity was
evaluated by trained neurologists using the National Institutes
of Health Stroke Scale (NIHSS) at admission and discharge [21].
2.3. Psychological measurement
The patients were assessed every day by the psychiatrist
from the day of their hospitalization to their discharge from
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was determined by clinical evaluation according to the
Statistical Manual of Mental Disorders, Fourth Edition [1]
criteria and used the Delirium Rating Scale (DRS) developed
by Trzepacz et al. [2]. This scale consists of 10 items ranging
between 0 and 3. Delirium is deﬁned when the score is 10
points or higher. Delirium subtypes were categorized as
hyperactive, hypoactive, and mixed, which have been
described by Liptzin and Levkoff and used in some previous
studies [22,23].
2.4. Blood collection and cytokine measurement
Blood samples were taken at the ﬁrst 24 h after stroke onset. A
total of 8 ml of peripheral venous blood was drawn and
centrifuged at 1000  g for 10 min at room temperature to
separate the blood components. Serum samples were kept at
80 8C until assay. TNF-alpha, IL-1 beta, IL-18, BDNF, NSE, and
serum levels were measured with enzyme-linked immuno-
sorbent assay (ELISA), using a commercial kit according to the
manufacturer's instructions (BDNF, IL-1b and TNFa: Boster
Biological Technology, California, USA; NSE: Yehua Biological
Technology, Shanghai, China; IL-18: eBioscienceBender Med-




Age (mean  SD) 64.63  13.18 
Sex, Male n (%) 24 (49) 
Sex, Female n (%) 25 (51) 
Habitation n (%)
City center 29 (59.2) 
Rural area 17 (34.7) 
Village 3 (6.1) 
Income status n (%)
High income 4 (8.2) 
Ordinary income 45 (91.8) 
Living condition n (%)
Live with family 45 (91.8) 
Live alone 9 (81.8) 
Medical history
HT n (%) 36 (73.5) 
DM n (%) 18 (36.7) 
CAD n (%) 12 (24.5) 
HL n (%) 11 (22.4) 
CHF n (%) 4 (8.2) 
AF n (%) 10 (20.4) 
Smoking n (%) 11 (22.4) 
ASA n (%) 17 (34.7) 
Anticoagulant n (%) 2(4.1) 
Antihypertensive n (%) 33 (67.3) 
OAD n (%) 13 (26.5) 
İnsülin n (%) 11 (22.4) 
Length of hospital stay (mean  SD) 11.08  5.63 
Functional scores
NIHSS at admission (mean  SD) 6.10  3.80 
NIHSS at discharge (mean  SD) 2.92  2.57 
Note: Signiﬁcant p values are boldfaced.2.5. Statistical analysis
Statistical analyses were performed with SPSS 16.0 for
Windows (Statistical Package for the Social Sciences, Chicago,
IL). For comparisons between the study groups t test (for
normally distributed variables) and Mann–Whitney U test (for
abnormally distributed variables) were used for continuous
variables and x2 test (for 3 or more  2 variables) or Fisher's
exact test (for 2  2 variables) for categorical variables. All
signiﬁcant levels were 2-tailed and set at the level of 0.05.
3. Results
The mean age of the study sample (n: 60) was 66.15  12.53
(range: 31–89) years. Thirty-one of the patients in the study
population (51.7%) were female and twenty-nine (48.3%) were
male. Thirty-six of the patients in the study group (60%) were
living in the city center, and 21 (35%) were living in rural areas,
54 (90%) were living with family and 54 (90%) belonged to the
normal income group. In the study group, Hypertension (HT)
(n: 45, 75%), Diabetes Mellitus (DM) (n: 23, 38.3%), Coronary
Artery Disease (CAD) (n: 18, 30%) and Hyperlipidemia (HL) (n:
16, 26.7%) were the most common diseases. The average NIHSSspital stay and functional scores of the patients.
Patient with AIS and delirium
n = 11
p






















16  5.17 0.010
10.36  5.88 0.021
5.73  3.87 0.014
Table 2 – Etiological classification and stroke location of the patients.
Patient with AIS
n = 49




Large artery n (%) 10 (20.4) 5 (45.5) 0.086
Cardio embolism n (%) 11 (22.4) 4 (36.4) 0.340
Small vessel disease n (%) 7 (14.3) 0 (0) 0.186
Undetermined n (%) 19 (38.8) 2 (18.2) 0.199
Other n (%) 2 (4.1) 0 (0) 0.499
Stroke location
TACI n (%) 1 (2) 3 (27.3) 0.017
PACI n (%) 27 (55.1) 6 (54.6) 1.000
POCI n (%) 14 (28.6) 2 (18.2) 0.710
LACI n (%) 7 (14.3) 0 (0) 0.330
Note: Signiﬁcant p value is boldfaced.
Table 3 – Biological parameters of the patients.
Patient with AIS
n = 49
Patient with AIS and Delirium n = 11 p
Biological parameters
BGL (mean  SD) 144.69  74.27 155.36  71.40 0.666
Urea (mean  SD) 39.36  15.63 44.00  16.49 0.383
Creatine (mean  SD) 0.30  0.46 0.36  0.50 0.717
Hemoglobin (mean  SD) 12.83  2.11 12.81  1.77 0.909
WBC (mean  SD) 8283.67  1983.93 8627.27  1884.72 0.603
CRP (mean  SD) 4.46  3.36 5.90  4.03 0.221
Uric acid (mean  SD) 5.16  1.72 5.45  2.01 0.625
TNF-alfa-pg/ml (mean  SD) 30.86  36.88 33.82  19.61 0.221
IL-1beta-pg/ml (mean  SD) 3.71  4.06 3.27  0.90 0.483
IL-18-pg/ml (mean  SD) 165.82  114.82 181.55  77.19 0.668
NSE-ng/ml (mean  SD) 5.39  5.53 5.18  3.51 1.000
BDNF-pg/ml (mean  SD) 1035.33  761.07 905.73  653.89 0.603
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be 6.88  4.52 and 3.43  3.02, respectively (Table 1). There was
no signiﬁcant difference between the delirious and nondelir-
ious in terms of sociodemographic characteristics or medical
histories.
In the study group, 11 (18.3%) of 60 patients were diagnosed
with delirium. The majority of delirium observed in the study
group (n: 8, 72.7%) was the hypoactive type. The hyperactive
delirium and mixed type delirium were diagnosed as (n: 2,
18.2%) and (n: 1, 9.1%), respectively. Delirium started in the ﬁrst
three days in 90% of patients and the average was 2.18  0.98
days (range: 1–4 days). Delirium resolved within seven days in
80% of patients and the average recovery time of patients was
5.50  2.63 days (range: 3–11).
The average length of stay of the patient group diagnosed
with delirium was 16  5.17 days, and the average length of stay
in the non-delirious patients group was 11.08  5.63 days ( p:
0.010). The average NIHSS on admission of the patient group
diagnosed with delirium and non-delirious patients group were
10.36  5.88 and 6.10  3.80, respectively ( p: 0.021). The average
NIHSS on discharge of the patient group diagnosed with
delirium and non-delirious patients group were 5.73  3.87 and
2.92  2.57, respectively ( p: 0.014). There was a signiﬁcant
difference between the delirious and non-delirious in terms of
length of hospital stay (from hospitalization to discharge from
the neurology department), NIHSS at admission, and NIHSS at
discharge (Table 1).As shown in Table 2, patients with AIS, (n: 15, 25%) were
classiﬁed as large artery disease, (n: 15, 25%) cardio embolic, (n:
21, 35%) undetermined, (n: 7, 11.7%) small vessel disease and
other etiology (n: 2, 3.3%). There was no signiﬁcant difference
between the delirious and nondelirious in terms of TOAST
classiﬁcation. Total anterior circulation infarcts (TACI), partial
anterior circulation infarcts (PACI), posterior circulation
infarcts (POCI) and lacunar infarcts (LACI) were found in (n:
4, 6.7%), (n: 33, 55%), (n: 16, 26.7%) and (n: 7, 11.7%) patients,
respectively. There was a signiﬁcant difference between the
delirious and non-delirious in terms of TACI.
The serum samples were taken at 11.58  3.04/hours after
the onset of AIS symptoms on average from the delirious
patient group, and at 12.02  2.58/hours after the onset of AIS
symptoms on average from the non-delirious patient group ( p:
0.587). As shown in Table 3, there was no signiﬁcant difference
between the delirious and non-delirious patients in terms of
hematologic and biochemical variables. In addition, serum
baseline levels of TNF-alpha, IL-1 beta, IL-18, NSE, and BDNF
were similar in the two groups.
4. Discussion
Delirium prevalence has been reported to be from 14% to 87%
in critically ill patients [7]. In this study the incidence of
delirium was 18.3%. A meta-analysis suggests that the
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25% in patients admitted to general internal medicine wards
[24], which is similar to the value detected in our study.
The relationship between the increase in serum TNF-alpha,
IL-1beta and IL-18 and NSE measured in patients diagnosed
with AIS, and infarct volume, severity of neurological deﬁcit
and neuronal death has been determined in studies [25–27]. In
addition to this, elevated blood levels of inﬂammatory markers
are associated with unfavorable functional outcome and
increased mortality after stroke [28]. Berretta A. et al. have
suggested that BDNF plays a key role in functional improve-
ment after AIS [29].
In our sample, we found that there was no signiﬁcant
relationship between delirium developed after AIS and pro-
inﬂammatory cytokines (TNF-alpha, IL-1beta, IL-18), BDNF and
NSE. As we know, our study is the ﬁrst investigating the
relationship between delirium developing in the patient group
followed in the non-intensive stroke unit due to AIS and pro-
inﬂammatory cytokines (TNF-alpha, IL-1beta, IL-18), BDNF and
NSE. The present studies investigating delirium after AIS have
not investigated biological factors, such as pro-inﬂammatory
cytokines, BDNF and NSE during AIS, and the development of
delirium. These studies examined mainly cerebral ischemic
and hemorrhagic events together rather than just ischemic
stroke and usually focused on delirium incidence, clinical
features, related clinical or demographic characteristics and
clinical outcomes [8,30–32]. Previous studies that examined
the relationship between delirium and inﬂammatory markers
were mostly conducted in patient groups that were followed
because of medical and surgical diseases in medical and
surgical intensive care units [15–18].
When the results of previous studies on patient groups
excepting cerebrovascular diseases were analyzed, high basal
pro-inﬂammatory cytokines, NSE and BDNF can be expected to
be related to the development of delirium in patients undergo-
ing AIS. However, our ﬁndings do not support this hypothesis.
This may include possible reasons such as: First, our expecta-
tions prior to studies about the parameters of this study stem
from ﬁndings obtained from studies conducted in patients
diagnosed with delirium during medical and surgical clinical
follow-up. The studies on the parameters mentioned did not
include the patient group with AIS. Second, the serum samples
were taken within the ﬁrst 24 h and this shows relatively basal
values of these parameters. However, the serum levels of these
parameters in patients may have the potential to undergo a
partial change in the period starting from the cerebrovascular
event until the time that serum samples were taken. Therefore,
the resulting serum levels may not fully reﬂect the value at the
moment of the development of the cerebrovascular event.
Third, that we have a study group consisting of patients with
mild to moderate stroke may have inﬂuenced our ﬁndings
about pro-inﬂammatory cytokines, BDNF and NSE.
Our study is particularly distinguished from earlier studies
and carries originality with two aspects: First, it aimed to
examine delirium developed following AIS within the plane of
basal pro-inﬂammatory cytokines, BDNF and NSE. A previous
study designed in this manner has not been found in the
literature. Second, most of the previous studies related to
delirium have been carried out in the intensive care unit. Our
study offers a new contribution to the literature on the subjectbecause it provides data regarding the patient group followed
in the non-intensive stroke unit and the patient exclusion
criteria of the study were designed taking into account many
situations that could affect the inﬂammatory response.
In the present study, there was a signiﬁcant difference
between the delirious and nondelirious in terms of age and
these results were similar to previous studies performed on
patients with AIS [10,12,30]. Older age is a predisposing factor
for the development of post-stroke delirium. It is known that
older age is a low-level inﬂammatory condition caused by
increased activity of natural immunity and neuroinﬂamma-
tion increases the cholinergic deﬁcit in patients with delirium
[33,34]. Although our study results showing that older age but
not baseline levels of serum proinﬂammatory cytokines
predict occurrence of delirium after AIS do not support this
hypothesis, further studies should be conducted on this topic.
It is known that delirium after AIS lengthens the duration of
hospitalization and this condition is associated with the
severity of the patients' neurological deﬁcit and hence
hospitalization functional status [10,11]. There was a signiﬁcant
difference between the delirious and non-delirious in terms of
the NIHSS of patients on admission and discharge and length of
stay in hospital. When our patient group was evaluated for
NIHSS, it could include patients with mild to moderate stroke
severity. The studies conducted until now were performed by
categorizing the severity of the stroke of patients and the
absence of large-scale studies planned in the framework of
delirium-inﬂammation relationship reduce the strength of the
reviews that we made on this issue. However, the ﬁndings of
this study suggest that delirium developing after AIS is
associated with stroke severity during hospitalization and
the development of delirium has a negative impact on duration
of hospital stay and functional recovery. It has been demon-
strated in many studies performed previously that delirium
had a negative effect on length of stay in hospital and the
disease course [10–12,32].
Previous studies have reported that stroke location is
associated with a greater risk of delirium. For example, it has
been reported with strokes within the anterior or dorsomedial
thalamus, the posterior cerebral artery territory, the bilateral
anterior cerebral artery territories, the inferior part of the genu
of the internal capsule, the caudate nucleus, and the middle
cerebral artery territory, particularly in the frontostriatal
region and middle temporal gyrus [35]. In the current study,
the Oxfordshire classiﬁcation criteria of cerebral infarction
were used [20] and it was found that delirium was more likely
to occur in patients with a TACI. Sheng et al. have revealed a
similar result [10].
Three clinical subtypes of delirium (hyperactive, hypoac-
tive, and mixed subtypes) have been deﬁned [22,23]. The
hypoactive type can often be undetected or misdiagnosed as
depression. Potentially, this means that delirium in acute
stroke may be missed, particularly the hypoactive type [11].
Results of the current study indicated that the most common
type of delirium following AIS was hypoactive. We found no
study regarding types of delirium in patients with AIS in the
literature. The levels of cytokine have been found to be higher
in the patient group with hyperactive delirium compared to
the patient group with hypoactive delirium in the studies
conducted by Munster et al. and it has been suggested that
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and the levels of cytokine [36]. Most of the patients with
delirium in our sample were the hypoactive type. This may be
another reason why we have not reached a conclusion with
statistical signiﬁcance between delirious and non-delirious
patient groups in terms of proinﬂammatory cytokines, BDNF
and NSE measurements
Some limitations should be considered when interpreting
our study ﬁndings. First, the study has a relatively small
sample size. Concerns that neuroinﬂammatory responses
may affect the study results led to rigidity of study exclusion
criteria and therefore the exclusion of a signiﬁcant portion of
the patients who could have been included in the study. In
addition, we think that to study the biological parameters by
creating groups that will need a high number of patients in a
single center would be pretty hard in the presence of the
exclusion criteria mentioned. Second, the study has a cross-
sectional but not prospective observational design. Serum
samples from the patient group were taken in the ﬁrst twelve
hours after AIS on average as we have expressed in the earlier
parts of the discussion. Ideally, taking blood samples accord-
ing to the temporal course of neuroinﬂammatory response can
provide more robust data on the relationship between
delirium and inﬂammatory biological parameters in patient
groups without diseases that can cause neuroinﬂammatory
response. Delirium after AIS was diagnosed by a psychiatrist as
a result of an assessment held with the psychiatric interview
instruments and the patients were followed during current
conditions. Despite all these limitations, there are major
strengths in our study.
5. Conclusion
Despite the limitations, our study ﬁndings show that delirium
in patients undergoing AIS was not associated with basal
serum pro-inﬂammatory cytokines (TNF-alpha, IL-1 beta, IL-
18), BDNF and NSE. Cross-sectional, multicenter, and prospec-
tive controlled studies in large samples are needed in order to
obtain more precise data and more accurate reviews.
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